Modulation of mAb quality attributes using microliter scale fed-batch cultures

Biotechnology Progress

Volumn 30, Issue 3, 2014, Pages 571-583

  Rouiller, Yolande ^a   Périlleux, Arnaud ^a   Vesin, Marie Noëlle ^a   Stettler, Matthieu ^a   Jordan, Martin ^a   Broly, Hervé ^a  

^a Merck Serono SA   (Switzerland)

Author keywords

CHO cells; High throughput; Monoclonal antibody; Process development; Quality attributes

Indexed keywords

CELLS; MONOCLONAL ANTIBODIES; SILICON COMPOUNDS;

CHO CELL; HIGH THROUGHPUT; HIGH-THROUGHPUT APPROACHES; INTRINSIC DIFFERENCES; LOW MOLECULAR WEIGHT; PROCESS DEVELOPMENT; PROCESS PERFORMANCE; QUALITY ATTRIBUTES;

BATCH CELL CULTURE;

CULTURE MEDIUM; MONOCLONAL ANTIBODY; POLYSACCHARIDE;

ANIMAL; BATCH CELL CULTURE; BIOREACTOR; BIOSYNTHESIS; CHO CELL LINE; CRICETULUS; CULTURE MEDIUM;

ANIMALS; ANTIBODIES, MONOCLONAL; BATCH CELL CULTURE TECHNIQUES; BIOREACTORS; CHO CELLS; CRICETULUS; CULTURE MEDIA; POLYSACCHARIDES;

EID: 84922838909     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.1921     Document Type: Article

References (99)

1. Amanullah A, Otero JM, Mikola M, Hsu A, Zhang J, Aunins J, Schreyer HB, Hope JA, Russo AP. Novel micro-bioreactor high throughput technology for cell culture process development: reproducibility and scalability assessment of fed-batch CHO cultures. Biotechnol Bioeng. 2010;106:57-67.
2. Bareither R, Pollard D. A review of advanced small-scale parallel bioreactor technology for accelerated process development: current state and future need. Biotechnol Prog. 2011;27:2-14.
3. Barrett TA, Wu A, Zhang H, Levy MS, Lye GJ. Microwell engineering characterization for mammalian cell culture process development. Biotechnol Bioeng. 2010;105:260-275.
4. Jordan M, Voisard D, Berthoud A, Tercier L, Kleuser B, Baer G, Broly H. Cell culture medium improvement by rigorous shuffling of components using media blending. Cytotechnology. 2013;65:31-40.
5. Moses S. Assessment of AMBRTM as a model for highthroughput cell culture process development strategy. Adv Biosci Biotechnol. 2012;03:918-927.
6. Rouiller Y, Périlleux A, Collet N, Jordan M, Stettler M, Broly H. A high-throughput media design approach for high performance mammalian fed-batch cultures. mAbs. 2013;5:501-511.
7. Zhong X, Wright JF. Biological insights into therapeutic protein modifications throughout trafficking and their biopharmaceutical applications. Int J Cell Biol. 2013;2013:273086.
8. Eon-Duval A, Broly H, Gleixner R. Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach. Biotechnol Prog. 2012;28:608-622.
9. Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem. 2010;21:2153-2163.
10. Bumbaca D, Boswell CA, Fielder PJ, Khawli LA. Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J. 2012;14:554-558.
11. Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X, Yao Z, Sreedhara A, Cano T, Tesar D, Nijem I, Allison DE, Wong PY, Kao YH, Quan C, Joshi A, Harris RJ, Motchnik P. Charge variants in IgG1: isolation, characterization, in vitro binding properties and pharmacokinetics in rats. MAbs. 2010;2:613-624.
12. Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J. Heterogeneity of monoclonal antibodies. J Pharm Sci. 2008;97: 2426-2447.
13. Du Y, Walsh A, Ehrick R, Xu W, May K, Liu H. Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies. MAbs. 2012;4:578-585.
14. He XZ, Que AH, Mo JJ. Analysis of charge heterogeneities in mAbs using imaged CE. Electrophoresis. 2009;30:714-722.
15. Hossler P, Khattak SF, Li ZJ. Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology. 2009;19: 936-949.
16. Jenkins N, Parekh RB, James DC. Getting the glycosylation right: implications for the biotechnology industry. Nat Biotechnol. 1996;14:975-981.
17. Lingg N, Zhang P, Song Z, Bardor M. The sweet tooth of biopharmaceuticals: importance of recombinant protein glycosylation analysis. Biotechnol J. 2012;7:1462-1472.
18. Sinclair AM, Elliott S. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci. 2005;94:1626-1635.
19. Sola RJ, Griebenow K. Effects of glycosylation on the stability of protein pharmaceuticals. J Pharm Sci. 2009;98:1223-1245.
20. Chung S, Quarmby V, Gao X, Ying Y, Lin L, Reed C, Fong C, Lau W, Qiu ZJ, Shen A, Vanderlaan M, Songn A. Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcc receptor binding and antibody-dependent cell-mediated cytotoxicity activities. mAbs. 2012;4:326-340.
21. Hodoniczky J, Yuan ZZ, James DC. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog. 2005;21:1644-1652.
22. Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, Shitara K, Satoh M. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology. 2007;17:104-118.
23. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006;313:670-673.
24. Masuda K, Kubota T, Kaneko E, Iida S, Wakitani M, Kobayashi-Natsume Y, Kubota A, Shitara K, Nakamura K. Enhanced binding affinity for FccRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Mol Immunol. 2007;44:3122-3131.
25. Naso MF, Tam SH, Scallon BJ, Raju TS. Engineering host cell lines to reduce terminal sialylation of secreted antibodies. mAbs. 2010;2:519-527.
26. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol. 2008;20:471-478.
27. Satoh M, Iida S, Shitara K. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther. 2006;6:1161-1173.
28. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. Lack of fucose on human IgG1 Nlinked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277:26733-26740.
29. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, Hanai N, Shitara K. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003; 278:3466-3473.
30. Wright A, Morrison SL. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mousehuman IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J Immunol. 1998;160:3393-3402.
31. Yu M, Brown D, Reed C, Chung S, Lutman J, Stefanich E, Wong A, Stephan JP, Bayer R. Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans. mAbs. 2012;4:475-487.
32. Zhou Q, Shankara S, Roy A, Qiu H, Estes S, McVie-Wylie A, Culm-Merdek K, Park A, Pan C, Edmunds T. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng. 2008;99:652-665.
33. Abès R, Teillaud J-L. Impact of glycosylation on effector functions of therapeutic IgG. Pharmaceuticals. 2010;3:146-158.
34. Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol. 2007;44: 1524-1534.
35. Jing Y, Borys M, Nayak S, Egan S, Qian Y, Pan SH, Li ZJ. Identification of cell culture conditions to control protein aggregation of IgG fusion proteins expressed in Chinese hamster ovary cells. Process Biochem. 2012;47:69-75.
36. Wang W, Nema S, Teagarden D. Protein aggregation-pathways and influencing factors. Int J Pharm. 2010;390:89-99.
37. Fradkin AH, Carpenter JF, Randolph TW. Immunogenicity of aggregates of recombinant human growth hormone in mouse models. J Pharm Sci. 2009;98:3247-3264.
38. Hermeling S, Crommelin DJA, Schellekens H, Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res. 2004;21:897-903.
39. Jenkins N, Murphy L, Tyther R. Post-translational modifications of recombinant proteins: significance for biopharmaceuticals. Mol Biotechnol. 2008;39:113-118.
40. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J. 2006;8:E501-E507.
41. Gao SX, Zhang Y, Stansberry-Perkins K, Buko A, Bai S, Nguyen V, Brader ML. Fragmentation of a highly purified monoclonal antibody attributed to residual CHO cell protease activity. Biotechnol Bioeng. 2011;108:977-982.
42. Page M, Ling C, Dilger P, Bentley M, Forsey T, Longstaff C, Thorpe R. Fragmentation of therapeutic human immunoglobulin preparations. Vox Sanguinis. 1995;69:183-194.
43. Vlasak J, Ionescu R. Fragmentation of monoclonal antibodies. mAbs. 2011;3:253-263.
44. del Val IJ, Kontoravdi C, Nagy JM. Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns. Biotechnol Prog. 2010;26:1505-1527.
45. Gramer MJ, Eckblad JJ, Donahue R, Brown J, Shultz C, Vickerman K, Priem P, van den Bremer ET, Gerritsen J, van Berkel PH. Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose. Biotechnol Bioeng. 2011;108:1591-1602.
46. Bareither R, Bargh N, Oakeshott R, Watts K, Pollard D. Automated disposable small scale reactor for high throughput bioprocess development: a proof of concept study. Biotechnol Bioeng. 2013;110:3126-3138.
47. Grainger RK, James DC. CHO cell line specific prediction and control of recombinant monoclonal antibody N-glycosylation. Biotechnol Bioeng. 2013;110:2970-2983.
48. Jordan M, Stettler M. Tools for high-throughput process and medium optimization. Methods Mol Biol. 2014;1104:77-88.
49. Khetan A, Huang YM, Dolnikova J, Pederson NE, Wen D, Yusuf-Makagiansar H, Chen P, Ryll T. Control of misincorporation of serine for asparagine during antibody production using CHO cells. Biotechnol Bioeng. 2010;107:116-123.
50. Wen D, Vecchi MM, Gu S, Su L, Dolnikova J, Huang YM, Foley SF, Garber E, Pederson N, Meier W. Discovery and investigation of misincorporation of serine at asparagine positions in recombinant proteins expressed in Chinese hamster ovary cells. J Biol Chem. 2009;284:32686-32694.
51. Jnaoui K, Minet M, Michiels T. Mutations that affect the tropism of DA and GDVII strains of Theiler's virus in vitro influence sialic acid binding and pathogenicity. J Virol. 2002;76: 8138-8147.
52. Pöschl E, Fox JW, Block D, Mayer U, Timpl R. Two noncontiguous regions contribute to nidogen binding to a single EGF-like motif of the laminin γ 1 chain. EMBO J. 1994;13: 3741-3747.
53. Stevens C, Lin Y, Sanchez M, Amin E, Copson E, White H, Durston V, Eccles DM, Hupp T. A germ line mutation in the death domain of DAPK-1 inactivates ERK-induced apoptosis. J Biol Chem. 2007;282:13791-13803.
54. Kaye EM, Shalish C, Livermore J, Taylor HA, Stevenson RE, Breakefield XO. beta-Galactosidase gene mutations in patients with slowly progressive GM1 gangliosidosis. J Child Neurol. 1997;12:242-247.
55. George E, Huisman TH, Yang KG, Kutlari F, Wilson JB, Kutlar A, Storming TA, Gonzales-Redondo JM, Faridah K, Khalid AK. First observation of haemoglobin Malay alpha 2B2 26 (B1) Asn-Ser-a case report. Med J Malay. 1989;44:259-262.
56. Igarashi K, Kashiwagi K. Modulation of cellular function by polyamines. Int J Biochem Cell Biol. 2010;42:39-51.
57. Landau G, Bercovich Z, Park MH, Kahana C. The role of polyamines in supporting growth of mammalian cells is mediated through their requirement for translation initiation and elongation. J Biol Chem. 2010;285:12474-12481.
58. Mandal S, Mandal A, Johansson HE, Orjalo AV, Park MH. Depletion of cellular polyamines, spermidine and spermine, causes a total arrest in translation and growth in mammalian cells. Proc Natl Acad Sci USA. 2013;110:2169-2174.
59. Seiler N, Raul F. Polyamines and apoptosis. J Cell Mol Med. 2005;9:623-642.
60. Williams K. Interactions of polyamines with ion channels. Biochem J. 1997;325:289-297.
61. Hendrickson TL, Imperiali B. Metal ion dependence of oligosaccharyl transferase: implications for catalysis. Biochemistry. 1995;34:9444-9450.
62. Witsell DL, Casey CE, Neville MC. Divalent cation activation of galactosyltransferase in native mammary golgi vesicles. J Biol Chem. 1990;265:15731-15737.
63. Zhang Y, Wang PG, Brew K. Specificity and mechanism of metal ion activation in UDP-galactose: β-galactoside-α-1,3-galactosyltransferase. J Biol Chem. 2001;276:11567-11574.
64. Welply JK, Shenbagamurthi P, Lennarz WJ, Naider F. Substrate recognition by oligosaccharyltransferase. Studies on glycosylation of modified Asn-X-Thr/Ser tripeptides. J Biol Chem. 1983; 258:11856-11863.
65. Crowell CK, Grampp GE, Rogers GN, Miller J, Scheinman RI. Amino acid and manganese supplementation modulates the glycosylation state of erythropoietin in a CHO culture system. Biotechnol Bioeng. 2007;96:538-549.
66. Gawlitzek M, Estacio M, Furch T, Kiss R. Identification of cell culture conditions to control N-glycosylation site-occupancy of recombinant glycoproteins expressed in CHO cells. Biotechnol Bioeng. 2009;103:1164-1175.
67. Altamirano C, Illanes A, Becerra S, Cairo JJ, Godia F. Considerations on the lactate consumption by CHO cells in the presence of galactose. J Biotechnol. 2006;125:547-556.
68. Arigony ALV, De Oliveira IM, Machado M, Bordin DL, Bergter L, Prá D, Henriques JAP. The influence of micronutrients in cell culture: a reflection on viability and genomic stability. BioMed Res Int. 2013;2013. http://dx.doi.org/10.1155/2013/597282.
69. Ganther HE. Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis. 1999;20:1657-1666.
70. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell. 2004; 117:285-297.
71. Hooper NM. Families of zinc metalloproteases. FEBS Lett. 1994; 354:1-6.
72. Luo J, Vijayasankaran N, Autsen J, Santuray R, Hudson T, Amanullah A, Li F. Comparative metabolite analysis to understand lactate metabolism shift in Chinese hamster ovary cell culture process. Biotechnol Bioeng. 2012;109:146-156.
73. Richardson DR, Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta Rev Biomembr. 1997;1331:1-40.
74. Saito Y, Yoshida Y, Akazawa T, Takahashi K, Niki E. Cell death caused by selenium deficiency and protective effect of antioxidants. J Biol Chem. 2003;278:39428-39434.
75. Tainer JA, Getzoff ED, Richardson JS, Richardson DC. Structure and mechanism of copper, zinc superoxide dismutase. Nature. 1983;306:284-287.
76. Vallee BL, Auld DS. Zinc coordination, function, and structure of zinc enzymes and other proteins. Biochemistry. 1990;29: 5647-5659.
77. Yoon SO, Kim MM, Park SJ, Kim D, Chung J, Chung AS. Selenite suppresses hydrogen peroxide-induced cell apoptosis through inhibition of ASK1/JNK and activation of PI3-K/Akt pathways. FASEB J Off Publ Federat Am Soc Exp Biol. 2002; 16:111-113.
78. Zeng H, Saari JT, Johnson WT. Copper deficiency decreases complex IV but not complex I, II, III, or V in the mitochondrial respiratory chain in rat heart. J Nutr. 2007;137:14-18.
79. Kim K, Rhee SG, Stadtman ER. Nonenzymatic cleavage of proteins by reactive oxygen species generated by dithiothreitol and iron. J Biol Chem. 1985;260:15394-15397.
80. Li S, Nguyen TH, Schoneich C, Borchardt RT. Aggregation and precipitation of human relaxin induced by metal-catalyzed oxidation. Biochemistry. 1995;34:5762-5772.
81. Marx G, Chevion M. Site-specific modification of albumin by free radicals. Reaction with copper(II) and ascorbate. Biochem J. 1986;236:397-400.
82. Zhou S, Zhang B, Sturm E, Teagarden DL, Schöneich C, Kolhe P, Lewis LM, Muralidhara BK, Singh SK. Comparative evaluation of disodium edetate and diethylenetriaminepentaacetic acid as iron chelators to prevent metal-catalyzed destabilization of a therapeutic monoclonal antibody. J Pharm Sci. 2010;99:4239-4250.
83. Duetz WA. Microtiter plates as mini-bioreactors: miniaturization of fermentation methods. Trends Microbiol. 2007;15: 469-475.
84. Wong NS, Wati L, Nissom PM, Feng HT, Lee MM, Yap MG. An investigation of intracellular glycosylation activities in CHO cells: effects of nucleotide sugar precursor feeding. Biotechnol Bioeng. 2010;107:321-336.
85. Bai Y, Wu C, Zhao J, Liu YH, Ding W, Ling WL. Role of iron and sodium citrate in animal protein-free CHO cell culture medium on cell growth and monoclonal antibody production. Biotechnol Prog. 2011;27:209-219.
86. Altamirano C, Berrios J, Vergara M, Becerra S. Advances in improving mammalian cells metabolism for recombinant protein production. Electronic J Biotechnol. 2013;16. http://www.ejbiotechnology.info. DOI: 10.2225.
87. Gawlitzek M, Ryll T, Lofgren J, Sliwkowski MB. Ammonium alters N-glycan structures of recombinant TNFR-IgG: degradative versus biosynthetic mechanisms. Biotechnol Bioeng. 2000; 68:637-646.
88. Gillmeister MP, Tomiya N, Jacobia SJ, Lee YC, Gorfien SF, Betenbaugh MJ. An HPLC-MALDI MS method for N-glycan analyses using smaller size samples: application to monitor glycan modulation by medium conditions. Glycoconjug J. 2009;26: 1135-1149.
89. Hong JK, Cho SM, Yoon SK. Substitution of glutamine by glutamate enhances production and galactosylation of recombinant IgG in Chinese hamster ovary cells. Appl Microbiol Biotechnol. 2010;88:869-876.
90. Pacis E, Yu M, Autsen J, Bayer R, Li F. Effects of cell culture conditions on antibody N-linked glycosylation-what affects high mannose 5 glycoform. Biotechnol Bioeng. 2011;108:2348-2358.
91. Chen P, Harcum SW. Effects of elevated ammonium on glycosylation gene expression in CHO cells. Metab Eng. 2006;8:123-132.
92. Van Berkel PHC, Gerritsen J, Perdok G, Valbjŕn J, Vink T, Van De Winkel JGJ, Parren PWHI. N-linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG. Biotechnol Prog. 2009;25:244-251.
93. Vijayasankaran N, Varma S, Yang Y, Mun M, Arevalo S, Gawlitzek M, Swartz T, Lim A, Li F, Zhang B, Meier S, Kiss R. Effect of cell culture medium components on color of formulated monoclonal antibody drug substance. Biotechnol Prog. 2013;29:1270-1277.
94. Yang M, Butler M. Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms. Biotechnol Prog. 2002;18:129-138.
95. Smith MA, Easton M, Everett P, Lewis G, Payne M, Riveros-Moreno V, Allen G. Specific cleavage of immunoglobulin G by copper ions. Int J Peptide Protein Res. 1996;48:48-55.
96. Chaderjian WB, Chin ET, Harris RJ, Etcheverry TM. Effect of copper sulfate on performance of a serum-free CHO cell culture process and the level of free thiol in the recombinant antibody expressed. Biotechnol Prog. 2005;21:550-553.
97. Trexler-Schmidt M, Sargis S, Chiu J, Sze-Khoo S, Mun M, Kao YH, Laird MW. Identification and prevention of antibody disulfide bond reduction during cell culture manufacturing. Biotechnol Bioeng. 2010;106:452-461.
98. Luo J, Zhang J, Ren D, Tsai WL, Li F, Amanullah A, Hudson T. Probing of C-terminal lysine variation in a recombinant monoclonal antibody production using Chinese hamster ovary cells with chemically defined media. Biotechnol Bioeng. 2012; 109:2306-2315.
99. Zhang J, Robinson D, Salmon P. A novel function for selenium in biological system: selenite as a highly effective iron carrier for Chinese hamster ovary cell growth and monoclonal antibody production. Biotechnol Bioeng. 2006;95:1188-1197.